公司资料

Lyra Therapeutics 股价、新闻与催化剂

股票代码:: LYRA
交易所:: NASDAQ
行业:: Biopharma
所在地:: United States

股票表现

0.01 USD (+2400.00%)

收盘价

最后更新: 2026年8月21日

—

市值

股价为何变动

As of Aug 21, 2026, LYRA closed up 2400.0% at $0.0100. No new same-company headline was identified in the current news window.

公司概览

业务概览

Lyra Therapeutics is an otolaryngology company focused on chronic rhinosinusitis and upper-airway disease. Its platform uses localized delivery to treat difficult ENT conditions.

所在地与行业分类

Headquartered in the United States and listed on NASDAQ, Lyra sits in specialty biotechnology.

商业模式特征

The company depends on clinical validation, delivery technology, and the ability to build a niche ENT franchise.

生物医药行业定位

Lyra is a niche ENT catalyst name whose stock is driven by clinical and regulatory progress.

未来催化剂

Lyra’s catalysts are its GI-surgery and reflux platform, along with any commercial update that shows the device base is still growing. The story is about procedure adoption more than binary events.